Powered by

ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel

Jun 02, 2021 - GlobeNewswire

Initial safety data showed combination regimen at the recommended Phase 2 dose was well tolerated; treatment-related adverse events primarily Grade 1 or 2, with no treatment-related discontinuations

ORIC-101 plasma concentrations provided excellent target coverage; no evidence of drug-drug interaction with nab-paclitaxel Translational data showed pharmacodynamic modulation of GR biomarkers and high rates of GR expression in tumor types of interest Antitumor activity demonstrated across...